S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
NASDAQ:INVA

Innoviva Competitors

$11.43
-0.19 (-1.64 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.42
Now: $11.43
$11.78
50-Day Range
$11.47
MA: $12.29
$12.87
52-Week Range
$7.58
Now: $11.43
$15.62
Volume677,000 shs
Average Volume558,450 shs
Market Capitalization$1.16 billion
P/E Ratio5.83
Dividend YieldN/A
Beta0.64

Competitors

Innoviva (NASDAQ:INVA) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying INVA stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Innoviva, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Innoviva (NASDAQ:INVA) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Volatility and Risk

Innoviva has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Innoviva and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Innoviva67.16%53.99%28.92%
Amgen29.42%95.55%15.52%

Institutional and Insider Ownership

71.5% of Innoviva shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 0.3% of Innoviva shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Innoviva and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innoviva$261.02 million4.44$157.29 million$1.437.99
Amgen$23.36 billion5.56$7.84 billion$14.8215.18

Amgen has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Innoviva and Amgen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Innoviva10001.00
Amgen0111402.56

Innoviva presently has a consensus target price of $10.00, indicating a potential downside of 12.51%. Amgen has a consensus target price of $256.0909, indicating a potential upside of 13.86%. Given Amgen's stronger consensus rating and higher possible upside, analysts plainly believe Amgen is more favorable than Innoviva.

Summary

Amgen beats Innoviva on 12 of the 14 factors compared between the two stocks.

Innoviva (NASDAQ:INVA) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Volatility and Risk

Innoviva has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Profitability

This table compares Innoviva and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Innoviva67.16%53.99%28.92%
Gilead Sciences5.48%37.77%12.76%

Institutional and Insider Ownership

71.5% of Innoviva shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 0.3% of Innoviva shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Innoviva and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innoviva$261.02 million4.44$157.29 million$1.437.99
Gilead Sciences$22.45 billion3.43$5.39 billion$6.1410.00

Gilead Sciences has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Innoviva and Gilead Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Innoviva10001.00
Gilead Sciences1121202.44

Innoviva presently has a consensus target price of $10.00, indicating a potential downside of 12.51%. Gilead Sciences has a consensus target price of $96.0370, indicating a potential upside of 56.41%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Innoviva.

Summary

Gilead Sciences beats Innoviva on 8 of the 14 factors compared between the two stocks.

Innoviva (NASDAQ:INVA) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Volatility and Risk

Innoviva has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares Innoviva and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Innoviva67.16%53.99%28.92%
Vertex Pharmaceuticals38.51%28.55%20.68%

Institutional and Insider Ownership

71.5% of Innoviva shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 0.3% of Innoviva shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Innoviva and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innoviva$261.02 million4.44$157.29 million$1.437.99
Vertex Pharmaceuticals$4.16 billion13.27$1.18 billion$4.2949.55

Vertex Pharmaceuticals has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Innoviva and Vertex Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Innoviva10001.00
Vertex Pharmaceuticals042312.89

Innoviva presently has a consensus target price of $10.00, indicating a potential downside of 12.51%. Vertex Pharmaceuticals has a consensus target price of $291.8462, indicating a potential upside of 37.31%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Innoviva.

Summary

Vertex Pharmaceuticals beats Innoviva on 12 of the 15 factors compared between the two stocks.

Innoviva (NASDAQ:INVA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Volatility and Risk

Innoviva has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Earnings and Valuation

This table compares Innoviva and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innoviva$261.02 million4.44$157.29 million$1.437.99
Regeneron Pharmaceuticals$7.86 billion6.14$2.12 billion$21.4720.99

Regeneron Pharmaceuticals has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

71.5% of Innoviva shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.3% of Innoviva shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Innoviva and Regeneron Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Innoviva10001.00
Regeneron Pharmaceuticals061512.77

Innoviva presently has a consensus target price of $10.00, indicating a potential downside of 12.51%. Regeneron Pharmaceuticals has a consensus target price of $625.8077, indicating a potential upside of 38.89%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Innoviva.

Profitability

This table compares Innoviva and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Innoviva67.16%53.99%28.92%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Summary

Regeneron Pharmaceuticals beats Innoviva on 11 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Risk and Volatility

Biogen has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Valuation & Earnings

This table compares Biogen and Innoviva's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.89$5.89 billion$33.578.13
Innoviva$261.02 million4.44$157.29 million$1.437.99

Biogen has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

83.5% of Biogen shares are owned by institutional investors. Comparatively, 71.5% of Innoviva shares are owned by institutional investors. 0.5% of Biogen shares are owned by company insiders. Comparatively, 0.3% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Biogen and Innoviva, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5151202.22
Innoviva10001.00

Biogen currently has a consensus price target of $304.4667, indicating a potential upside of 11.58%. Innoviva has a consensus price target of $10.00, indicating a potential downside of 12.51%. Given Biogen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Biogen is more favorable than Innoviva.

Profitability

This table compares Biogen and Innoviva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Innoviva67.16%53.99%28.92%

Summary

Biogen beats Innoviva on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Risk and Volatility

Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Valuation & Earnings

This table compares Alexion Pharmaceuticals and Innoviva's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion6.73$2.40 billion$9.7415.68
Innoviva$261.02 million4.44$157.29 million$1.437.99

Alexion Pharmaceuticals has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.5% of Innoviva shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Alexion Pharmaceuticals and Innoviva, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017712.36
Innoviva10001.00

Alexion Pharmaceuticals currently has a consensus price target of $153.1250, indicating a potential upside of 0.25%. Innoviva has a consensus price target of $10.00, indicating a potential downside of 12.51%. Given Alexion Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alexion Pharmaceuticals is more favorable than Innoviva.

Profitability

This table compares Alexion Pharmaceuticals and Innoviva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Innoviva67.16%53.99%28.92%

Summary

Alexion Pharmaceuticals beats Innoviva on 12 of the 15 factors compared between the two stocks.


Innoviva Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$224.92-1.2%$129.91 billion$23.36 billion18.14
Gilead Sciences logo
GILD
Gilead Sciences
2.8$61.40-2.3%$76.97 billion$22.45 billion63.30
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$212.55-0.2%$55.25 billion$4.16 billion26.84
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$450.57-0.6%$48.27 billion$7.86 billion16.47
Biogen logo
BIIB
Biogen
1.9$272.88-1.6%$41.57 billion$14.38 billion9.03
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$152.75-0.6%$33.58 billion$4.99 billion35.69Increase in Short Interest
Seagen logo
SGEN
Seagen
1.5$151.11-0.7%$27.38 billion$916.71 million59.49Decrease in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.6$136.12-3.5%$23.02 billion$876.29 million-61.59
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$148.10-1.0%$17.33 billion$219.75 million-18.91
Incyte logo
INCY
Incyte
1.9$78.66-0.3%$17.29 billion$2.16 billion-50.10
Novavax logo
NVAX
Novavax
1.2$231.23-4.2%$14.72 billion$18.66 million-44.30
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.43-5.6%$14.06 billion$1.70 billion17.72Earnings Announcement
High Trading Volume
Repligen logo
RGEN
Repligen
1.5$212.39-2.5%$11.18 billion$270.24 million259.01Earnings Announcement
Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.1$109.51-2.5%$10.29 billion$788.10 million117.75Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.7$167.18-1.0%$7.43 billion$1.45 billion15.82Earnings Announcement
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.2$52.40-1.9%$7.33 billion$1.12 billion109.17Earnings Announcement
Analyst Revision
News Coverage
Exelixis logo
EXEL
Exelixis
1.9$21.66-1.4%$6.76 billion$967.78 million45.13Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$45.25-4.6%$6.12 billion$195.99 million282.81Earnings Announcement
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$96.00-1.2%$5.12 billion$1.11 billion30.87
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$80.35-1.1%$4.85 billion$806.43 million-11.38Earnings Announcement
Analyst Revision
ChemoCentryx logo
CCXI
ChemoCentryx
1.4$67.84-2.9%$4.70 billion$36.13 million-101.25Decrease in Short Interest
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$12.28-2.9%$3.20 billion$182.24 million-10.68
Alkermes logo
ALKS
Alkermes
1.2$19.04-2.1%$3.03 billion$1.17 billion-41.39
OPKO Health logo
OPK
OPKO Health
1.9$4.50-1.8%$3.02 billion$901.90 million-25.00Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.22-1.3%$2.38 billion$120.28 million-149.72Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$30.49-0.9%$2.29 billion$638.60 million-11.73Earnings Announcement
Decrease in Short Interest
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.78-2.9%$1.90 billion$48.83 million-14.18Earnings Announcement
Analyst Report
Analyst Revision
Gap Down
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$121.19-1.5%$1.87 billionN/A-10.95Earnings Announcement
Analyst Report
Analyst Revision
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.75-0.3%$1.70 billion$82.27 million-21.34
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.49-2.6%$1.63 billion$102.43 million-19.15Earnings Announcement
High Trading Volume
Analyst Revision
News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.5$9.23-2.1%$1.48 billion$428.41 million13.38
MannKind logo
MNKD
MannKind
1.4$5.71-1.8%$1.33 billion$63.04 million-27.19Analyst Report
Codexis logo
CDXS
Codexis
1.1$22.11-3.9%$1.31 billion$68.46 million-63.17Earnings Announcement
Analyst Report
Gap Down
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.1$5.33-12.8%$1.14 billion$150,000.00-7.61Earnings Announcement
Analyst Report
High Trading Volume
Gap Down
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$27.08-1.6%$1.07 billion$3.57 million-12.14
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$18.65-3.8%$1.02 billion$227.19 million51.81
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.75-6.7%$964.01 million$35.22 million-6.39Earnings Announcement
Analyst Downgrade
Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.8$7.19-4.0%$871.31 million$322.07 million-6.85Gap Up
Agenus logo
AGEN
Agenus
1.6$4.00-2.3%$760.60 million$150.05 million-3.67
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$21.66-6.4%$714.61 million$252 million-2.21Earnings Announcement
Analyst Report
High Trading Volume
Analyst Revision
Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.15-0.2%$701.27 million$59.29 million-27.66Upcoming Earnings
Gap Down
Curis logo
CRIS
Curis
1.1$9.84-0.9%$578.76 million$10 million-12.00Increase in Short Interest
Geron logo
GERN
Geron
1.4$1.79-1.1%$555.75 million$460,000.00-5.11
Molecular Templates logo
MTEM
Molecular Templates
2.0$10.90-1.1%$544.61 million$22.27 million-5.34
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.99-0.8%$529.03 million$143.01 million-1.14Earnings Announcement
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.43-5.0%$500.51 million$109.33 million-2.52
XOMA logo
XOMA
XOMA
1.8$36.20-0.0%$399.00 million$18.37 million-32.61Decrease in Short Interest
Verastem logo
VSTM
Verastem
1.8$2.35-0.4%$398.97 million$17.46 million-1.67
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$3.72-0.3%$348.58 million$36.63 million-4.38Analyst Report
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-9.3%$282.14 million$54.76 million-2.19High Trading Volume
This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.